4//SEC Filing
GILL DAVID N 4
Accession 0001106519-25-000005
CIK 0001722964other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 9:27 PM ET
Size
26.8 KB
Accession
0001106519-25-000005
Insider Transaction Report
Form 4
GILL DAVID N
Director
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2025-09-16−33,450→ 0 totalExercise: $4.51Exp: 2035-06-30→ Common Stock (33,450 underlying) - Disposition to Issuer
Common Stock
2025-09-16−25,080→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2025-09-16−14,545→ 0 totalExercise: $12.01Exp: 2034-06-11→ Common Stock (14,545 underlying) - Disposition to Issuer
Common Stock
2025-09-16$8.60/sh−5,825$50,095→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2025-09-16−24,000→ 0 totalExercise: $11.16Exp: 2028-04-24→ Common Stock (24,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-09-16−13,950→ 0 totalExercise: $8.13Exp: 2033-06-08→ Common Stock (13,950 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-09-16−16,000→ 0 totalExercise: $21.45Exp: 2029-06-12→ Common Stock (16,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-09-16−11,000→ 0 totalExercise: $48.67Exp: 2030-06-23→ Common Stock (11,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-09-16−11,000→ 0 totalExercise: $37.53Exp: 2031-06-10→ Common Stock (11,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-09-16−16,000→ 0 totalExercise: $16.64Exp: 2032-07-15→ Common Stock (16,000 underlying)
Footnotes (5)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
- [F2]Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration.
- [F3]Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU.
- [F4]At the Effective Time, pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.
- [F5]At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.
Documents
Issuer
Y-mAbs Therapeutics, Inc.
CIK 0001722964
Entity typeother
Related Parties
1- filerCIK 0001106519
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 9:27 PM ET
- Size
- 26.8 KB